116855-03-9 Usage
Uses
Used in Pharmaceutical Industry:
3-BROMO-1-METHYL-1H-PYRAZOLO[3,4-B]PYRIDINE is used as a building block for the synthesis of various bioactive molecules and pharmaceutical drugs. Its versatile chemical structure allows for the creation of new compounds with potential therapeutic applications.
Used in Neurological Disorders Treatment:
3-BROMO-1-METHYL-1H-PYRAZOLO[3,4-B]PYRIDINE has been studied for its potential applications in the treatment of neurological disorders. Its chemical properties may contribute to the development of new treatments for conditions affecting the nervous system.
Used in Anticancer Research:
3-BROMO-1-METHYL-1H-PYRAZOLO[3,4-B]PYRIDINE is also being investigated as an anti-cancer agent. Its unique structure may offer new avenues for the development of cancer therapies, potentially leading to more effective treatments for various types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 116855-03-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,6,8,5 and 5 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 116855-03:
(8*1)+(7*1)+(6*6)+(5*8)+(4*5)+(3*5)+(2*0)+(1*3)=129
129 % 10 = 9
So 116855-03-9 is a valid CAS Registry Number.
116855-03-9Relevant articles and documents
Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists
Orr, Suvi T. M.,Beveridge, Ramsay,Bhattacharya, Samit K.,Cameron, Kimberly O.,Coffey, Steven,Fernando, Dilinie,Hepworth, David,Jackson, Margaret V.,Khot, Vishal,Kosa, Rachel,Lapham, Kimberly,Loria, Paula M.,McClure, Kim F.,Patel, Jigna,Rose, Colin,Saenz, James,Stock, Ingrid A.,Storer, Gregory,Von Volkenburg, Maria,Vrieze, Derek,Wang, Guoqiang,Xiao, Jun,Zhang, Yingxin
supporting information, p. 156 - 161 (2015/03/04)
Several polar heteroaromatic acetic acids and their piperidine amides were synthesized and evaluated as ghrelin or type 1a growth hormone secretagogue receptor (GHS-R1a) inverse agonists. Efforts to improve pharmacokinetic and safety profile was achieved